Company intelligence / Profile preview
NRx Pharmaceuticals
Wilmington, Delaware, United Statesaccessnewswire.com ↗
- Ownership
- Public · NRXP
- Employees
- ~10
- Development stage
- Phase 3
01
Overview
NRx’s lead candidate NRX‑101 has shown positive Phase 2 results in reducing suicidality and depressive symptoms in patients with severe bipolar depression. It received FDA Breakthrough Therapy Designation and Special Protocol Assessment. A pivotal Phase 3 trial for severe bipolar depression with acute suicidality began dosing patients in early 2023. The company’s proprietary IV ketamine formulation (NRX‑100) has begun NDA submission as of late December 2024 targeting suicidal depression.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (notably oral fixed-dose combinations and IV formulations)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Alvogen, Inc.Lotus Pharmaceutical Co. Ltd.Apkarian TechnologiesGlytech LLCSarah Herzog Memorial HospitalNephron Pharmaceuticals
04
Financials
- Market cap
- $60M
- Total revenue
- $1.1M
- Enterprise value
- $34.5M
Beyond the preview
Go deeper on NRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRx Pharmaceuticals.